A Double-Blind, Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma.
Latest Information Update: 29 Feb 2024
At a glance
- Drugs ASM 8 (Primary)
- Indications Allergic asthma
- Focus Biomarker; Therapeutic Use
- Sponsors Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2011 Results of this trial are anticipated in the second quarter of 2012, according to a Pharmaxis media release.